| Doctor's visit | price on request |
| Heart Valve Replacement | $14000 - $23000 |
| Coronary stenting | $4500 - $6500 |
| Coronary artery bypass grafting | $27000 |
Dr. Bernhard Reimers – Clinical and Invasive Cardiology Unit Director in Humanitas Research Hospital, was born in Germany. He graduated in medicine and surgery in University of Padua (Italy) in 1990, followed by specialization in Cardiology. During the first 3 years of specialization in Cardiology in the Coronary Unit of Padua University, his particular interests were in managing cardiovascular urgency and critical patients, including management of fans, balloon pump, hemofiltration, temporary pacing, placement of central venous pathways and Swan-Ganz catheter. He spent his last year of specialization at the Hemodynamics of Casa di Cura Columbus (Milan), where he acquired his knowledge on the main diagnostic techniques he uses. After a short period of study at the Thoraxcenter of Rotterdam, during which he wrote his first scientific publications, Dr. Reimers has dedicated himself to hemodynamics and cardiovascular surgeries, working as Unit Director main assistant, executing angioplasty, coronary and peripheral procedures, reaching complete autonomy in coronary stenting, atherectomy, ultrasound intravascular and intracoronary doppler.
Since September 1997 he has managed and developed the diagnostic and interventional cardiovascular program at the Department of Cardiology of Mirano (Venice), where, thanks to his achievements, since 2000 the highest number of coronary angioplasties were performed. In 2006 the Unit has performed 975 coronary angioplasties (including 125 primary), more than 400 carotid angioplasty and peripherals. Dr. Reimers became Unit Director and has trained and taught a young team of interventional cardiologists, including 4 completely independent in the performance of coronary angioplasty, which manages both hemodynamics and largely the CCU in close collaboration between the two services. After this important experience, he was invited to be part of Humanitas Research Hospital as Clinical and Invasive Cardiology Unit Director.
Dr. Reimers participates in many scientific studies on the treatment of myocardial infarction considering new interventional or pharmaceutical approaches for primary angioplasty. He was also member of the Technical Commission of the Regional Bid for the purchase of stents. Thanks to Dr. Reimers’ efforts, Hemodynamics of Mirano (Venice) is considered reference center for primary angioplasty and elective complex procedures. Dr. Reimers is considered to be one of the leading experts of carotid angioplasty worldwide. He is preparing a program for interventional treatment of acute stroke. He performs routine renal angioplasty and implants percutaneous devices and endoprosthesis systems for aortic aneurysms.
Dr. Reimers has published, as author or co-author, 77 articles quoted in Medline. The impact factor calculated based on 2006 is 263. He published 9 book chapters and several abstracts for important international conferences dedicated to Cardiology, such as TCT, PCR, National GISE ANMCO, JIM and ESC, were he also performed live invasive procedures.
Dr. Reimers has always considered participation in clinical trials and scientific international events among the main activities of his professional carrier. Besides teaching at University of Tor Vergata in Rome, he organizes many conferences, national and international medical follow-up courses. For over 9 years he has been organizing theoretical and practical courses with lectures and transmission of live procedures in Venice. He has so far organized two editions of TOBI, international meeting dedicated to invasive treatment of total coronary occlusions and bifurcations, three editions of ETI, international conference and the largest in Italy, dedicated to invasive cardiology devices.
Dr. Reimers was member of the scientific committee in the editions of 2006 and 2007 of National Convention GISE (Italian Group of Hemodynamic Study) and participated at important events dedicated to CAPTURE study, ESIRIUS, SYNTAX, TIMI 38, FINESSE and many others.
Dr. Bernhard Reimers – Clinical and Invasive Cardiology Unit Director in Humanitas Research Hospital, was born in Germany. He graduated in medicine and surgery in University of Padua (Italy) in 1990, followed by specialization in Cardiology. During the first 3 years of specialization in Cardiology in the Coronary Unit of Padua University, his particular interests were in managing cardiovascular urgency and critical patients, including management of fans, balloon pump, hemofiltration, temporary pacing, placement of central venous pathways and Swan-Ganz catheter. He spent his last year of specialization at the Hemodynamics of Casa di Cura Columbus (Milan), where he acquired his knowledge on the main diagnostic techniques he uses. After a short period of study at the Thoraxcenter of Rotterdam, during which he wrote his first scientific publications, Dr. Reimers has dedicated himself to hemodynamics and cardiovascular surgeries, working as Unit Director main assistant, executing angioplasty, coronary and peripheral procedures, reaching complete autonomy in coronary stenting, atherectomy, ultrasound intravascular and intracoronary doppler.
Since September 1997 he has managed and developed the diagnostic and interventional cardiovascular program at the Department of Cardiology of Mirano (Venice), where, thanks to his achievements, since 2000 the highest number of coronary angioplasties were performed. In 2006 the Unit has performed 975 coronary angioplasties (including 125 primary), more than 400 carotid angioplasty and peripherals. Dr. Reimers became Unit Director and has trained and taught a young team of interventional cardiologists, including 4 completely independent in the performance of coronary angioplasty, which manages both hemodynamics and largely the CCU in close collaboration between the two services. After this important experience, he was invited to be part of Humanitas Research Hospital as Clinical and Invasive Cardiology Unit Director.
Dr. Reimers participates in many scientific studies on the treatment of myocardial infarction considering new interventional or pharmaceutical approaches for primary angioplasty. He was also member of the Technical Commission of the Regional Bid for the purchase of stents. Thanks to Dr. Reimers’ efforts, Hemodynamics of Mirano (Venice) is considered reference center for primary angioplasty and elective complex procedures. Dr. Reimers is considered to be one of the leading experts of carotid angioplasty worldwide. He is preparing a program for interventional treatment of acute stroke. He performs routine renal angioplasty and implants percutaneous devices and endoprosthesis systems for aortic aneurysms.
Dr. Reimers has published, as author or co-author, 77 articles quoted in Medline. The impact factor calculated based on 2006 is 263. He published 9 book chapters and several abstracts for important international conferences dedicated to Cardiology, such as TCT, PCR, National GISE ANMCO, JIM and ESC, were he also performed live invasive procedures.
Dr. Reimers has always considered participation in clinical trials and scientific international events among the main activities of his professional carrier. Besides teaching at University of Tor Vergata in Rome, he organizes many conferences, national and international medical follow-up courses. For over 9 years he has been organizing theoretical and practical courses with lectures and transmission of live procedures in Venice. He has so far organized two editions of TOBI, international meeting dedicated to invasive treatment of total coronary occlusions and bifurcations, three editions of ETI, international conference and the largest in Italy, dedicated to invasive cardiology devices.
Dr. Reimers was member of the scientific committee in the editions of 2006 and 2007 of National Convention GISE (Italian Group of Hemodynamic Study) and participated at important events dedicated to CAPTURE study, ESIRIUS, SYNTAX, TIMI 38, FINESSE and many others.
Dr. Lucia Torracca is leading the Cardiac Surgery Unit at Humanitas Research Hospital. She received her training at Ospedali Civili di Brescia and at Ospedale San Raffaele with Professor Ottavio Alfieri, were she improved her knowledge in the mitral disease focusing in the reparative and preservative approaches. At the same institution she led the minimal invasive and robotic division before moving to Ospedali Riuniti Di Ancona to be chief of the Cardiac Surgery Complex Unit. Dr. Torracca has performed more than 55 hundred cardiac surgeries. Thanks to her surgical and academic curriculum, she has been an active member of the steering committee of the European Society editing Guidelines for the treatment of heart diseases.
Together with her team in Humanitas, she can approach every cardiac disease affecting adults, especially focusing on the minimal invasive approach to reparative valve disease. State of the art technologies are regularly explored and implemented in the Open Heart dedicated Operating Room and Intensive Care Unit to ensure best outcomes, shorter hospital stay and fewer surgical complications.
The surgical expertise of Dr. Torracca go from open heart circulatory-arrest procedure to off-pump and/or trans-catheter procedures (MitraClip or TransApical Aortic Valve Implants).
Dr. Torracca and her team can claim the highest rate of mitral valve repair in Bi-leaflet prolapse (Barlow Disease) hitting almost 99% of conservative approach in minimal invasiveness at the time of surgery, maintaining >95% success rate at long term follow up: this option is further advantageous in the youngest patient population allowing restrain from anticoagulation therapy and perfectly normal quality of life.
Author or co-author of 151 publications in national and international scientific journals.
Read more
Dr. Lucia Torracca is leading the Cardiac Surgery Unit at Humanitas Research Hospital. She received her training at Ospedali Civili di Brescia and at Ospedale San Raffaele with Professor Ottavio Alfieri, were she improved her knowledge in the mitral disease focusing in the reparative and preservative approaches. At the same institution she led the minimal invasive and robotic division before moving to Ospedali Riuniti Di Ancona to be chief of the Cardiac Surgery Complex Unit. Dr. Torracca has performed more than 55 hundred cardiac surgeries. Thanks to her surgical and academic curriculum, she has been an active member of the steering committee of the European Society editing Guidelines for the treatment of heart diseases.
Together with her team in Humanitas, she can approach every cardiac disease affecting adults, especially focusing on the minimal invasive approach to reparative valve disease. State of the art technologies are regularly explored and implemented in the Open Heart dedicated Operating Room and Intensive Care Unit to ensure best outcomes, shorter hospital stay and fewer surgical complications.
The surgical expertise of Dr. Torracca go from open heart circulatory-arrest procedure to off-pump and/or trans-catheter procedures (MitraClip or TransApical Aortic Valve Implants).
Dr. Torracca and her team can claim the highest rate of mitral valve repair in Bi-leaflet prolapse (Barlow Disease) hitting almost 99% of conservative approach in minimal invasiveness at the time of surgery, maintaining >95% success rate at long term follow up: this option is further advantageous in the youngest patient population allowing restrain from anticoagulation therapy and perfectly normal quality of life.
Author or co-author of 151 publications in national and international scientific journals.
Dr. Mehdi Afrit is a Medical Oncologist who practices at Burjeel Specialty Hospital in Sharjah. He has over 11 years of experience caring for and managing cancer patients. He has extensive experience providing chemotherapy, hormonal therapy, immunotherapy, and targeted therapy to patients. He earned a Certificate of Medical Oncology from the Gustave Roussy Institute in Paris, France, where he received training in antitumor chemotherapy and cancer medical treatment. Additionally, he holds an international certificate in breast diseases. He also has a certificate in Good Clinical Practice from Trans Celerate Biopharma Inc. and a certificate in Clinical Trial Management: Good Clinical Practice from the Faculty of Pharmaceutical Medicine of the Royal College of Physicians. He previously worked for over five years as an Assistant Professor of Medical Oncology at Tunis’s Faculty of Medicine. He later practiced as a Consultant, Medical Oncologist for six years at Arianna’s hospital in Tunisia. He later worked for two years as a Specialist Medical Oncologist at Zulekha Hospital. He was also an investigator in three international clinical trials and holds clinical trial auditing and CRO certifications and a GCP Training Certificate from 2016. He is a member in good standing of the Emirates Oncology Society (EOS), the European Society of Medical Oncology (ESMO), and the American Society of Clinical Oncology (ASCO). His clinical expertise includes but is not limited to the following:
Dr. Mehdi Afrit is a Medical Oncologist who practices at Burjeel Specialty Hospital in Sharjah. He has over 11 years of experience caring for and managing cancer patients. He has extensive experience providing chemotherapy, hormonal therapy, immunotherapy, and targeted therapy to patients. He earned a Certificate of Medical Oncology from the Gustave Roussy Institute in Paris, France, where he received training in antitumor chemotherapy and cancer medical treatment. Additionally, he holds an international certificate in breast diseases. He also has a certificate in Good Clinical Practice from Trans Celerate Biopharma Inc. and a certificate in Clinical Trial Management: Good Clinical Practice from the Faculty of Pharmaceutical Medicine of the Royal College of Physicians. He previously worked for over five years as an Assistant Professor of Medical Oncology at Tunis’s Faculty of Medicine. He later practiced as a Consultant, Medical Oncologist for six years at Arianna’s hospital in Tunisia. He later worked for two years as a Specialist Medical Oncologist at Zulekha Hospital. He was also an investigator in three international clinical trials and holds clinical trial auditing and CRO certifications and a GCP Training Certificate from 2016. He is a member in good standing of the Emirates Oncology Society (EOS), the European Society of Medical Oncology (ESMO), and the American Society of Clinical Oncology (ASCO). His clinical expertise includes but is not limited to the following:
Mustafa Güden was born in 1965 in Kayseri, Turkey. After graduating from Kadıköy Anadolu High School, he completed his medical education at Istanbul University, Çapa Medical Faculty in 1989. He earned his specialization in Cardiovascular Surgery at Istanbul University’s Institute of Cardiology and went on to work for 10 years at Şişli Florence Nightingale Hospital. During this time, he also completed a short-term training at the OLV Clinic in Belgium.
In 2004, Dr. Güden became an Associate Professor, and in 2013, he was promoted to full Professorship. From 2016 to 2022, he served as a Cardiovascular Surgeon at Medipol Mega University Hospital. In 2023, he opened his private practice in Kadıköy, Istanbul.
You can connect with Mustafa Güden on LinkedIn here.
Mustafa Güden was born in 1965 in Kayseri, Turkey. After graduating from Kadıköy Anadolu High School, he completed his medical education at Istanbul University, Çapa Medical Faculty in 1989. He earned his specialization in Cardiovascular Surgery at Istanbul University’s Institute of Cardiology and went on to work for 10 years at Şişli Florence Nightingale Hospital. During this time, he also completed a short-term training at the OLV Clinic in Belgium.
In 2004, Dr. Güden became an Associate Professor, and in 2013, he was promoted to full Professorship. From 2016 to 2022, he served as a Cardiovascular Surgeon at Medipol Mega University Hospital. In 2023, he opened his private practice in Kadıköy, Istanbul.
You can connect with Mustafa Güden on LinkedIn here.